Related Experiment Video

Updated: Jul 5, 2026

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Immune intervention with monoclonal antibodies targeting CD152 (CTLA-4) for autoimmune and malignant diseases

Li-Te Chin1, Chishih Chu, Han-Min Chen

  • 1Graduate Institute of Life Science, Fu-Jen Catholic University, Taipei, Taiwan, ROC.

Chang Gung Medical Journal
|April 19, 2008
PubMed

Insights

Cytotoxic T lymphocyte antigen-4 (CTLA-4) plays a key role in T cell regulation and is a target for cancer immunotherapy. New research reveals its importance in regulatory T cells (Tregs) and how antibodies targeting it can act as agonists or antagonists.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • CD152, also known as cytotoxic T lymphocyte antigen-4 (CTLA-4), is a critical receptor for negative T cell regulation.
  • Its inhibitory function makes it a significant target for treating autoimmunity and a promising candidate for cancer immunotherapy.

Purpose of the Study:

  • To review recent advancements in monoclonal antibodies (mAbs) targeting CD152.
  • To explore how different mAbs, by binding to distinct epitopes, can modulate CD152 activity as agonists, antagonists, or inverse agonists.

Main Methods:

  • Literature review of recent progress in CD152-targeting mAbs.
  • Analysis of the distinct functional impacts of mAbs based on epitope specificity.

Main Results:

  • Emerging evidence highlights CD152's role in regulatory T cell (Treg) homeostasis and function.
  • Monoclonal antibodies targeting CD152 exhibit varied modulatory effects (agonist, antagonist, inverse agonist) depending on their epitope binding.

Conclusions:

  • Understanding the nuanced roles of CD152 and the differential effects of mAbs is crucial for optimizing immunotherapy strategies.
  • Targeting CD152 offers potential for both autoimmune disease treatment and enhanced cancer immunotherapy.

More Related Videos

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...